ENANTA PHARMACEUTICALS INC (ENTA): CEO Jay R. Luly, Ph.D. to retire

Events in this filing

Item 5.02 as filed

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 28, 2026, Enanta Pharmaceuticals, Inc. (the “Company”) and Jay R. Luly, Ph.D., age 70, announced Dr. Luly’s intention to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the Company. The Company expects to enter into an agreement with Dr. Luly for his continued service as a strategic advisor for the remainder of 2027. The Board of Directors (the “Board”) of the Company has initiated a comprehensive search for Dr. Luly’s successor, considering both internal and external candidates.
In addition, on October 28, 2026, the Board appointed Tara L. Kieffer, Ph.D., to the newly created role of Chief Operating Officer. Biographical and other information regarding Dr. Kieffer, age 48, is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on January 26, 2026, under the section “Executive Officers,” and such biographical information is incorporated herein by reference. Dr. Kieffer has not entered into any material plan, contract, arrangement or amendment in connection with this appointment. There is no family relationship between Dr. Kieffer and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer and Dr. Kieffer does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.